Business Performance Review

11.94 8.57 33.7% m 2,093 EBITDA PAT (In Millions) EBITDA Margin 33.7% 1,950 29.0% 1,725 21.0% 1,069 19.4% 1.050 23.6% 1,464 PAT PAT Margin 23.4% 1,355 19.9% 1,187 EPS (In ) 8.72 11.05 9.69 H1 FY23 H1 FY23 H1FY24 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 FY23 FY23 FY23 FY24 FY24 FY23 FY23 FY23 FY24 FY24 FY23 FY23 FY23 Q1 FY24 Q2 FY24 Q2 Q3 Q4 Q1 Q2 FY23 FY23 FY23 FY24 FY24 17.5% 31.0% 31.3% 21.6% 21.7% 3,675 11,738 9,992 3,099 20.7 17.6 2,542 2,156 30.2% 28.1% Q2 & H1 FY24 Performance Strong growth with stable margins Revenue (In Millions) 16.9% EBITDA (In Millions) 6,213 5,407 5,093 5,785 5,954 1,537 1,521 H1 FY23 H1 FY23 H1 FY24 H1 FY24 4 H1 FY24 Є Glenmark LIFE SCIENCES

View entire presentation